PDCD4 and ovarian cancer: Two different studies found that miR-182 overexpression, by negatively regulating programmed cell death 4 (PDCD4), was involved in chemoresistance exacerbation of lung and ovarian cancers to cisplatin and paclitaxel, respectively (233, 234).